An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy.

Trial Profile

An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Archimedes Development Limited
  • Most Recent Events

    • 03 Jul 2012 Planned number of patients 500 added as reported by EudraCT.
    • 03 Jul 2012 Additional trial locations identified as reported by EudraCT.
    • 27 Sep 2011 18-month results presented at the 2011 European Multidisciplinary Cancer Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top